---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000446"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:42:49.206831+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity

## Summary
- Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.
- Quarterly minimum fees reduced: $84,000 for May & Aug 2024, then $174,000 through Aug 2025.
- Previous schedule had fees up to $332,500/quarter from Nov 2025; now capped at $174,000.
- Amendment effective March 15, 2024; signed by all parties on March 21, 2024.
- Parentco assumed obligations after acquiring Premier in November 2023.

## SEC filing metadata
- accession: 0001640334-24-000446
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.0
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/0001640334-24-000446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000446
- JSON: https://secwatch.observer/filing/0001640334-24-000446.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.